IL211944A - METHOD OF DECISION If a patient with colorectal cancer (CRC) is likely to benefit from a drug inhibitor receptor factor epidermal monoclonal antibody directed to the EGFR pathway - Google Patents

METHOD OF DECISION If a patient with colorectal cancer (CRC) is likely to benefit from a drug inhibitor receptor factor epidermal monoclonal antibody directed to the EGFR pathway

Info

Publication number
IL211944A
IL211944A IL211944A IL21194411A IL211944A IL 211944 A IL211944 A IL 211944A IL 211944 A IL211944 A IL 211944A IL 21194411 A IL21194411 A IL 21194411A IL 211944 A IL211944 A IL 211944A
Authority
IL
Israel
Prior art keywords
crc
patient
benefit
treatment
determining whether
Prior art date
Application number
IL211944A
Other languages
English (en)
Hebrew (he)
Other versions
IL211944A0 (en
Original Assignee
Biodesix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodesix Inc filed Critical Biodesix Inc
Publication of IL211944A0 publication Critical patent/IL211944A0/en
Publication of IL211944A publication Critical patent/IL211944A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Computing Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Data Mining & Analysis (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
IL211944A 2009-01-20 2011-03-24 METHOD OF DECISION If a patient with colorectal cancer (CRC) is likely to benefit from a drug inhibitor receptor factor epidermal monoclonal antibody directed to the EGFR pathway IL211944A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/321,394 US7858390B2 (en) 2006-03-31 2009-01-20 Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
PCT/US2009/006267 WO2010085234A1 (en) 2009-01-20 2009-11-20 Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway

Publications (2)

Publication Number Publication Date
IL211944A0 IL211944A0 (en) 2011-06-30
IL211944A true IL211944A (en) 2014-01-30

Family

ID=41571343

Family Applications (1)

Application Number Title Priority Date Filing Date
IL211944A IL211944A (en) 2009-01-20 2011-03-24 METHOD OF DECISION If a patient with colorectal cancer (CRC) is likely to benefit from a drug inhibitor receptor factor epidermal monoclonal antibody directed to the EGFR pathway

Country Status (10)

Country Link
US (1) US7858390B2 (https=)
EP (1) EP2347261B1 (https=)
JP (1) JP4997345B2 (https=)
KR (1) KR101131231B1 (https=)
AU (1) AU2009338173B2 (https=)
CA (1) CA2744394A1 (https=)
ES (1) ES2392805T3 (https=)
IL (1) IL211944A (https=)
TW (1) TWI366671B (https=)
WO (1) WO2010085234A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7858390B2 (en) 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
CN102770760A (zh) * 2010-02-24 2012-11-07 佰欧迪塞克斯公司 利用质谱分析选择施用治疗剂的癌症患者
US8914238B2 (en) 2011-01-28 2014-12-16 Biodesix, Inc. Method for predicting breast cancer patient response to endocrine therapy
MX365418B (es) 2012-06-26 2019-06-03 Biodesix Inc Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.
AU2013287262A1 (en) 2012-07-05 2015-02-26 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
US10037874B2 (en) 2014-12-03 2018-07-31 Biodesix, Inc. Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry
WO2017011439A1 (en) 2015-07-13 2017-01-19 Biodesix, Inc. Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods
CA3011719A1 (en) 2016-01-21 2017-07-27 Protein Dynamic Solutions Llc Method and system for spectral data analysis
US11710539B2 (en) 2016-02-01 2023-07-25 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
WO2017176423A1 (en) 2016-04-08 2017-10-12 Biodesix, Inc. Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy
WO2018129301A1 (en) * 2017-01-05 2018-07-12 Biodesix, Inc. Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups
US20210369775A1 (en) 2017-12-15 2021-12-02 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
US12094587B2 (en) 2018-03-29 2024-09-17 Biodesix, Inc. Apparatus and method for identification of primary immune resistance in cancer patients
US20230386662A1 (en) * 2020-10-19 2023-11-30 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Rapid and direct identification and determination of urine bacterial susceptibility to antibiotics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101107765B1 (ko) 2002-08-06 2012-01-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암의 검출을 위한 생물 마커의 용도
AU2004248140A1 (en) 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
US20050267689A1 (en) 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
WO2005010492A2 (en) 2003-07-17 2005-02-03 Yale University Classification of disease states using mass spectrometry data
US20090204334A1 (en) 2004-03-30 2009-08-13 Eastern Virginia Medical School Lung cancer biomarkers
US20060029574A1 (en) 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
CA2612183C (en) * 2005-06-28 2015-08-11 Genentech, Inc. Egfr and kras mutations
WO2007109571A2 (en) * 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7858390B2 (en) 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway

Also Published As

Publication number Publication date
KR101131231B1 (ko) 2012-03-28
EP2347261B1 (en) 2012-08-15
ES2392805T3 (es) 2012-12-14
AU2009338173A1 (en) 2010-07-29
TW201028687A (en) 2010-08-01
US7858390B2 (en) 2010-12-28
US20090170216A1 (en) 2009-07-02
EP2347261A1 (en) 2011-07-27
TWI366671B (en) 2012-06-21
IL211944A0 (en) 2011-06-30
HK1156696A1 (en) 2012-06-15
KR20110061605A (ko) 2011-06-09
JP4997345B2 (ja) 2012-08-08
CA2744394A1 (en) 2010-07-29
WO2010085234A1 (en) 2010-07-29
JP2012507033A (ja) 2012-03-22
AU2009338173B2 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
IL211944A (en) METHOD OF DECISION If a patient with colorectal cancer (CRC) is likely to benefit from a drug inhibitor receptor factor epidermal monoclonal antibody directed to the EGFR pathway
LTPA2019503I1 (lt) Modifikuotų T ląstelių, turinčių chimerinų antigeno receptorių, panaudojimas vėžio gydymui
IL242204A0 (en) Monoclonal antibodies for cancer treatment
ZA201200408B (en) Biomarkers amd methods for determining efficacy of anti-egfr antibodies in cancer therapy
ZA201303803B (en) Humanized antibodies to liv-1 and use of same to treat cancer
IL219978A0 (en) Method to use gene expresssion to determine likelihood of clinical outcome of renal cancer
IL222657A0 (en) Antibodies against epidermal growth factor receptor (egfr) and uses thereof
EP2417984A4 (en) METHOD FOR THE TREATMENT OF BLOOD CANCER BY ANTI-TIM ANTIBODY
PT2550296T (pt) Anticorpos monoclonais para tratamento do cancro
IL218011A0 (en) Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
IL201666A0 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
IL221058B (en) Anti-vegf antibody for the treatment of ovarian cancer
ZA201300218B (en) Treatment of blood cancer
SG11201400919RA (en) Patient stratification and determining clinical outcome for cancer patients
IL213975A0 (en) Treatment of cancer with a humanized anti-egfr igg1 antibody and inriotecan
ZA200905833B (en) Monoclonal antibodies for treatment of cancer
MX2014006182A (es) Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr.
EP2544005A4 (en) MAGIC CREAM MARKERS AND METHOD FOR DETECTING GASTRIC CANCER
EP2402439A4 (en) IMMUNIZATION PROCEDURE WITH CANCER CELL
WO2012009576A9 (en) Prevention and treatment of pain using monoclonal antibodies and antibody fragments to lysophosphatidic acid
EP2586453A4 (en) ON GALACTOSYLCERAMIDE EXPRESSION FACTOR-1 OBJECTIVE TUMOR GROWTH CONTROL PROCEDURE
HK1181057A (en) Monoclonal antibodies for treatment of cancer
NZ717883A (en) Monoclonal antibodies against her2
HK1186096A (en) Prevention and treatment of pain using monoclonal antibodies and antibody fragments to lysophosphatidic acid

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees